Company profile: Amnis
1.1 - Company Overview
Company description
- Provider of flow cytometry products and services used in research and clinical studies, including investigating the immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant. Offers Cytek Aurora spectral cytometer, Aurora CS cell sorter, Northern Lights, Orion reagent prep, ESP Detection Option, and Cytek Amnis AI v3.0 image analysis software.
Products and services
- Cytek Aurora CS: A high-sensitivity cell sorter combining Full Spectrum Profiling with high-end sorting to identify and isolate rare cell populations with exceptional resolution and accuracy
- Cytek Aurora: A full-spectrum spectral flow cytometry system delivering high-resolution data on complex cell populations and enabling diverse fluorochrome combinations without reconfiguring the instrument
- Cytek Northern Lights: A 24-color full spectrum flow cytometry instrument for everyday research, using one to three laser configurations to detect up to 24 colors with flexible, affordable operation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Amnis
Nanna Therapeutics
HQ: United Kingdom
Website
- Description: Provider of drug discovery platforms targeting fundamental cellular processes in age-related diseases. Offers the Nanoscale Medicines Discovery Engine for novel drugs addressing mitochondrial dysfunction and the Totally Integrated Medicines Engine (TIME), conducting 100 million phenotypic assays per hour to identify small-molecule leads for mitochondrial, neurodegenerative, cardiovascular/metabolic, joint/tissue diseases and cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanna Therapeutics company profile →
Inixium
HQ: Canada
Website
- Description: Provider of customer-centric CRO services offering critical knowledge-based expertise in structural biology to biotech and pharmaceutical industries globally throughout the early phases of drug discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inixium company profile →
Xcellerex
HQ: United States
Website
- Description: Provider of biomanufacturing technologies, developing and producing biomanufacturing systems and production-scale bioreactors that transform the speed and economics of producing therapeutic proteins, including biosimilars and vaccines. Offers OptiRun service solutions including maintenance, upgrades, calibration, remote support, plus equipment installation and qualification, scientific support, and training.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xcellerex company profile →
PacBio
HQ: United States
Website
- Description: Provider of sequencing systems and technologies for genomic, epigenomic, and transcriptomic analysis, including Revio long-read sequencing, Onso short-read with Sequencing by Binding (SBB) for high accuracy, rare variant detection and difficult-region analysis, Sequel IIe for HiFi reads in whole-genome and RNA sequencing, HiFi sequencing, and Kinnex kits for high-throughput RNA workflows (full-length, single-cell, 16S rRNA).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PacBio company profile →
Sloning Biotechnology
HQ: Germany
Website
- Description: Provider of tailored protein engineering solutions for industrial and biopharmaceutical sectors, leveraging the patented Slonomics technology platform to build DNA molecules with exceptional features regarding sequence limitations, reliability, and production cost on an industrial-scale robotic system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sloning Biotechnology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Amnis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Amnis
2.2 - Growth funds investing in similar companies to Amnis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Amnis
4.2 - Public trading comparable groups for Amnis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →